Rettinger E
Transfus Med Hemother. 2025; 52(1):77-95.
PMID: 39944412
PMC: 11813276.
DOI: 10.1159/000540964.
Mohsen E, Haffez H, Ahmed S, Hamed S, El-Mahdy T
Mol Neurobiol. 2025; .
PMID: 39934561
DOI: 10.1007/s12035-025-04728-5.
Luri-Rey C, Teijeira A, Wculek S, de Andrea C, Herrero C, Lopez-Janeiro A
Nat Rev Cancer. 2025; .
PMID: 39881005
DOI: 10.1038/s41568-024-00785-5.
Khan M, Sedgwick A, Sun Y, Vivian J, Corbett A, Dolcetti R
Front Immunol. 2025; 15:1474652.
PMID: 39877370
PMC: 11772185.
DOI: 10.3389/fimmu.2024.1474652.
Coenon L, Geindreau M, Ghiringhelli F, Villalba M, Bruchard M
Cell Death Dis. 2024; 15(8):614.
PMID: 39179536
PMC: 11343846.
DOI: 10.1038/s41419-024-06976-0.
Making a Monkey out of Human Immunodeficiency Virus/Simian Immunodeficiency Virus Pathogenesis: Immune Cell Depletion Experiments as a Tool to Understand the Immune Correlates of Protection and Pathogenicity in HIV Infection.
Symmonds J, Gaufin T, Xu C, Raehtz K, Ribeiro R, Pandrea I
Viruses. 2024; 16(6.
PMID: 38932264
PMC: 11209256.
DOI: 10.3390/v16060972.
Emerging strategies for treating autoimmune disease with genetically modified dendritic cells.
Ma Y, Shi R, Li F, Chang H
Cell Commun Signal. 2024; 22(1):262.
PMID: 38715122
PMC: 11075321.
DOI: 10.1186/s12964-024-01641-7.
Dual Activity of Type III PI3K Kinase Vps34 is Critical for NK Cell Development and Senescence.
Chen S, Li Z, Feng J, Quan Y, He J, Hao J
Adv Sci (Weinh). 2024; 11(21):e2309315.
PMID: 38544346
PMC: 11151045.
DOI: 10.1002/advs.202309315.
Late-Stage Ovarian Cancer With Systemic Multiple Metastases Shows Marked Shrinkage Using a Combination of Wilms' Tumor Antigen 1 (WT1) Dendritic Cell Vaccine, Natural Killer (NK) Cell Therapy, and Nivolumab.
Nagai H, Karube R
Cureus. 2024; 16(3):e56685.
PMID: 38523872
PMC: 10960621.
DOI: 10.7759/cureus.56685.
Actin cytoskeleton remodeling at the cancer cell side of the immunological synapse: good, bad, or both?.
Ockfen E, Filali L, Pereira Fernandes D, Hoffmann C, Thomas C
Front Immunol. 2023; 14:1276602.
PMID: 37869010
PMC: 10585106.
DOI: 10.3389/fimmu.2023.1276602.
Non-classical HLA-E restricted CMV 15-mer peptides are recognized by adaptive NK cells and induce memory responses.
Almazan N, Sala B, Sandalova T, Sun Y, Resink T, Cichocki F
Front Immunol. 2023; 14:1230718.
PMID: 37809084
PMC: 10552778.
DOI: 10.3389/fimmu.2023.1230718.
Hacking the Immune Response to Solid Tumors: Harnessing the Anti-Cancer Capacities of Oncolytic Bacteria.
Roe J, Seely K, Bussard C, Eischen Martin E, Mouw E, Bayles K
Pharmaceutics. 2023; 15(7).
PMID: 37514190
PMC: 10384176.
DOI: 10.3390/pharmaceutics15072004.
T cells, NK cells, and tumor-associated macrophages in cancer immunotherapy and the current state of the art of drug delivery systems.
Yang Y, Yang F, Huang Z, Li Y, Shi H, Sun Q
Front Immunol. 2023; 14:1199173.
PMID: 37457707
PMC: 10348220.
DOI: 10.3389/fimmu.2023.1199173.
Cell-based and cell-free immunotherapies for glioblastoma: current status and future directions.
Wang M, Wang X, Jin X, Zhou J, Zhang Y, Yang Y
Front Immunol. 2023; 14:1175118.
PMID: 37304305
PMC: 10248152.
DOI: 10.3389/fimmu.2023.1175118.
The Function of NK Cells in Tumor Metastasis and NK Cell-Based Immunotherapy.
Yu Y
Cancers (Basel). 2023; 15(8).
PMID: 37190251
PMC: 10136863.
DOI: 10.3390/cancers15082323.
Antibody conjugates for targeted delivery of Toll-like receptor 9 agonist to the tumor tissue.
Corogeanu D, Zaki K, Beavil A, Arnold J, Diebold S
PLoS One. 2023; 18(3):e0282831.
PMID: 36913398
PMC: 10010539.
DOI: 10.1371/journal.pone.0282831.
NK cells are never alone: crosstalk and communication in tumour microenvironments.
Zhou Y, Cheng L, Liu L, Li X
Mol Cancer. 2023; 22(1):34.
PMID: 36797782
PMC: 9933398.
DOI: 10.1186/s12943-023-01737-7.
4-1BB and cytokines trigger human NK, γδ T, and CD8 T cell proliferation and activation, but are not required for their effector functions.
Vidard L
Immun Inflamm Dis. 2023; 11(1):e749.
PMID: 36705415
PMC: 9753824.
DOI: 10.1002/iid3.749.
The Latest Approach of Immunotherapy with Endosomal TLR Agonists Improving NK Cell Function: An Overview.
Veneziani I, Alicata C, Moretta L, Maggi E
Biomedicines. 2023; 11(1).
PMID: 36672572
PMC: 9855813.
DOI: 10.3390/biomedicines11010064.
Exhaustion and over-activation of immune cells in COVID-19: Challenges and therapeutic opportunities.
Alahdal M, Elkord E
Clin Immunol. 2022; 245:109177.
PMID: 36356848
PMC: 9640209.
DOI: 10.1016/j.clim.2022.109177.